Phase I Trial of Concurrent Hyperfractionated Split Course Radiotherapy (HFx RT), Cisplatin (cDDP), and Paclitaxel in Patients with Recurrent, Previously Irradiated, or Treatment-Naïve Locally Advanced Upper Aerodigestive Malignancy

REFERENCES

• Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin. Oncol. 1988; 15: 70–85, [CSA]
   PubMed Web of Science ®Google Scholar
• Forastiere A. A., Metch B., Schuller D. E., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck. A Southwest Oncology Group Study. J. Clin. Oncol. 1992; 10: 1245–1251, [CSA]
   PubMed Web of Science ®Google Scholar
• Jacobs C., Lyman G., Velez-Garcia E., et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 1992; 10: 257–263, [CSA]
   PubMed Web of Science ®Google Scholar
• Coughlin C. T., Richmond R. C. Biologic and clinical development of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Semin. Oncol. 1989, Suppl. 6: 31, [CSA]
   PubMedGoogle Scholar
• Tischler R. B., Geard C. R., Hall E. J., et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 992; 52: 3495–3497, [CSA]
   Google Scholar
• Choy H., Rodriquez F. F., Koester S., et al. Investigation of taxol as a potential radiation sensitizer. Cancer 1993; 71: 3774–3778, [CSA]
   PubMed Web of Science ®Google Scholar
• Liebmann J., Cook J. A., Fisher J, et al. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst. 994; 86: 441–446, [CSA]
   Google Scholar
• Choy H., Browne M. J. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin. Oncol. 1995; 22(3)70–74, Suppl. 6[CSA]
   PubMed Web of Science ®Google Scholar
• Schaake-Koning C., Vanden Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N. Engl. J. Med. 1992; 326: 524–530, [CSA]
   PubMed Web of Science ®Google Scholar
• Hazuka M., Crowley J., Bunn P., et al. Concurrent daily low dose cisplatin (LDCP) combined with chest irradiation (RT) in locally advanced non-small cell lung cancer: preliminary results of a SWOG study. Proc. Am. Soc. Clin. Oncol. 1992; 11: 295, [CSA]
   Google Scholar
• Adelstein D., Adams G. L., Li Y., et al. Phase III comparison of standard radiation therapy versus radiation plus concurrent cisplatin versus split course RT plus concurrent cisplatin and 5-fluorouracil in patients with unresectable squamous cell head and neck cancer: an intergroup study. Proc. Am. Soc. Clin. Oncol. 2000; A–1624, [CSA]
   Google Scholar
• Forastiere A. A., et al. Use of paclitaxel in squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. 1995; 22(3)70–74, Suppl 6[CSA]
   Google Scholar
• Chang A., Kim K., Glick J., et al. Phase II study of paclitaxel in patients with stage IV non-small cell lung cancer: the Eastern Cooperative Group (ECOG) results. J. Natl. Cancer. Inst. 1993; 85: 388–393, [CSA]
   PubMed Web of Science ®Google Scholar
• Murphy W. R., Winn R. T., Rossella F. V., et al. A phase II study of paclitaxel (NSC 125973) in patients with non-small cell l ung cancer. J. Natl. Cancer Inst. 1993; 85: 384–387, [CSA]
   PubMed Web of Science ®Google Scholar
• Gatzmeier U., Pawel J. R, Heckmayer M., Neuhass R., Schluter I. Phase II study with paclitaxel in advanced, inoperable non-small cell lung cancer (NSCLC). The European experience. Lung Cancer 1994; 11(Suppl 2)236, [CSA]
   Google Scholar
• Vokes E. E., Haraf D. J., Mick R., et al. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J. Clin. Oncol. 1994; 12: 2351–2359, [CSA]
   PubMed Web of Science ®Google Scholar
• Spencer S., Wheeler R., Meredith R., Petus G., Robert F., Kim R., Walter M. Simultaneous hydroxyurea, 5-fluorouracil and high dose b.i.d. irradiation in previously irradiated patients with recurrent squamous cell cancer of the head and neck. Third International Conference on Head and Neck Cancer, San Francisco, CA, July, 1992
   Google Scholar
• Vokes E. E., Moormeier J. A., Ratain M. J., et al. 5-fluorouracil, leucovorin, hydroxyurea and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother. Pharmacol. 1992; 29: 178–184, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bunn P. A., Crowley J., Hazuka M., et al. The role of GM-CSF in limited stage SCLC: a randomized phase III study of the Southwest Oncology Group (SWOG). Proc. Am. Soc. Clin. Oncol. 1992; 11: A–974, [CSA]
   Google Scholar
• Momin F., Kraut M., Lattin P., et al. Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 1992; 11: A–983, [CSA]
   Google Scholar
• Crawford J., Ozer H., Stoller R., et al. Reduction by colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N. Engl. J. Med. 1991; 325: 164–170, [CSA]
   PubMed Web of Science ®Google Scholar
• Langlois D., Eschwege F., Kramar A., Richard J. M. Re-irradiation of head and neck cancers. Radiother. Oncol. 1985; 3: 27–33, [CSA]
   PubMed Web of Science ®Google Scholar
• Pomp J., Levendag P. C., van Putten W. L.J. Re-irradiation of recurrent tumors in the head and neck. Am J. Clin. Oncol. 1988; 11: 543–549, [CSA]
   PubMed Web of Science ®Google Scholar
• Skolyszewski J., Korzeniowski S., Reinfuss M. The re-irradiation of recurrences of head and neck cancer. Br. J. Radiol. 1980; 53: 462–465, [CSA]
   PubMed Web of Science ®Google Scholar
• Stevens K. R., Britsch A., Moss W. T. High-dose re-irradiation of head and neck cancer with curative intent. Int. J. Radiat. Oncol. Biol. Phys. 1994; 29: 687–698, [CSA]
   PubMed Web of Science ®Google Scholar
• Emami B., Marks J. E. Re-treatment of recurrent carcinoma of the head and neck by after loading interstitial 192IR implant. Laryngoscope 1983; 93: 1345–1347, [CSA]
   PubMed Web of Science ®Google Scholar
• Mazeron J. J., Langlois D., Glaubiger D., Huart J., Martin M. Salvage irradiation of oropharyngeal cancers using iridium 192 wire implants: 5-year results of 70 cases. Int. J. Radiat. Oncol. Biol. Phys. 1987; 13: 957–962, [CSA]
   PubMed Web of Science ®Google Scholar
• Puthawala A. A., Syed A. M.N. Interstitial re-irradiation for recurrent and/or persistent head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 1987; 13: 1113–1114, [CSA]
   PubMed Web of Science ®Google Scholar
• Phase II study of concurrent split course hyperfractionated XRT, cisplatin and paclitaxel in previously irradiated squamous cell carcinoma of the head and neck, RTOG 9911
   Google Scholar
• Hendry J. H., Rosenberg I., Greene D., Stewart J. G. Re-irradiation of rat tails to necrosis at six months after treatment with a tolerancy dose of x-ray or neutrons. Br. J. Radiol. 1977; 50: 567–573, [CSA]
   PubMed Web of Science ®Google Scholar
• Brown J. M., Probert J. C. Early and late radiation changes following a second course of irradiation. Radiology 1975; 115: 711–716, [CSA]
   PubMed Web of Science ®Google Scholar
• Jeremic B., Djuric L., Mijatovic L. Incidence of radiation myelitis of the cervical spine at doses of 5500 cGy or greater. Cancer 1991; 68: 2138–2141, [CSA]
   PubMed Web of Science ®Google Scholar